Tag: cancer biology
-
BATF2: A Novel Tumor Suppressor Silenced by Glutamine in Head and Neck Cancer
Overview: BATF2 and its role in immune surveillance Researchers from The University of Texas MD Anderson Cancer Center have identified BATF2 as a novel tumor suppressor that helps coordinate immune responses against head and neck cancers. In healthy tissue, BATF2 is part of a transcriptional network that supports anti-tumor immunity. The new work reveals that,…
-
YJBM Calls for Manuscripts: Mitochondria in Health and Disease Issue
Overview The Yale Journal of Biology and Medicine (YJBM) is announcing a dedicated issue focused on mitochondria in health and disease. This special edition invites researchers from across biology, medicine, and allied fields to contribute original research articles, comprehensive reviews, and perspective pieces exploring how mitochondrial function and dysfunction influence health, aging, metabolism, neurodegeneration, cancer,…
-
CTHRC1-driven Breast Cancer Progression: Palmitoylation Networks and Spatial Heterogeneity
Overview: Unraveling CTHRC1’s Role in Breast Cancer Breast cancer remains the most common malignancy affecting women worldwide, demanding deeper insights into its molecular drivers. Among emerging players, CTHRC1 has gained attention for its potential to modulate tumor progression through diverse signaling circuits. This article synthesizes current knowledge on how CTHRC1 influences breast cancer dynamics, with…
-
IFITM3-MET Interaction Drives Osimertinib Resistance in EGFR-Mutant NSCLC
Overview: A New Mechanism Behind Osimertinib Resistance in EGFR-Mutant NSCLC Osimertinib has transformed the treatment landscape for patients with EGFR-mutant non-small cell lung cancer (NSCLC). Yet resistance remains a major hurdle. A recent study identifies a non-genetic mechanism: the membrane protein IFITM3 interacts with MET to activate the PI3K-AKT signaling axis, enabling tumor cells to…
-
IFITM3-MET Interaction Drives Osimertinib Resistance in NSCLC
Overview: A cytokine-driven route to osimertinib resistance in EGFR-mutant NSCLC Osimertinib has transformed treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC) but resistance remains a critical hurdle. A combination of clinical data, tumor profiling, and functional studies now implicates IFITM3, a small antiviral membrane protein, in mediating resistance. The key finding is that…
-
Cancer Cells’ Hidden Power Source Revealed
Introduction: A surprising energy boost under pressure Scientists have uncovered a surprising mechanism that helps cancer cells survive the brutal mechanical gauntlets they must run to spread through the body. When cancer cells squeeze through dense tumor matrices, pores in blood vessels, and the bloodstream itself, they encounter intense physical stress. A team at the…